IntelliPharmaCeutics International Inc (IPCI)

0.97
0.01 1.04
NASDAQ : Health Care
Prev Close 0.96
Open 0.90
Day Low/High 0.88 / 1.10
52 Wk Low/High 1.41 / 3.67
Volume 242.11K
Avg Volume 329.00K
Exchange NASDAQ
Shares Outstanding 30.57M
Market Cap 33.32M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

The Klein Law Firm Notifies Investors Of Class Actions Filed On Behalf Of Intellipharmaceutics International Inc. Shareholders And A Lead Plaintiff Deadline Of September 29, 2017

The Klein Law Firm Notifies Investors Of Class Actions Filed On Behalf Of Intellipharmaceutics International Inc. Shareholders And A Lead Plaintiff Deadline Of September 29, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Intellipharmaceutics International Inc.

IPCI INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Intellipharmaceutics International Inc. And A Lead Plaintiff Deadline Of September 29, 2017

IPCI INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Intellipharmaceutics International Inc. And A Lead Plaintiff Deadline Of September 29, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Intellipharmaceutics...

IPCI SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Intellipharmaceutics International Inc. And A Lead Plaintiff Deadline Of September 29, 2017

IPCI SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Intellipharmaceutics International Inc. And A Lead Plaintiff Deadline Of September 29, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Intellipharmaceutics...

IPCI NOTICE: Rosen Law Firm Reminds Intellipharmaceutics International Inc. Investors Of Important Deadline In Class Action

IPCI NOTICE: Rosen Law Firm Reminds Intellipharmaceutics International Inc. Investors Of Important Deadline In Class Action

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intellipharmaceutics International Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed A Complaint To Recover Losses Suffered By Investors In Intellipharmaceutics International Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed A Complaint To Recover Losses Suffered By Investors In Intellipharmaceutics International Inc.

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Intellipharmaceutics International Inc.

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Intellipharmaceutics International Inc.

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Intellipharmaceutics International Inc.

The Klein Law Firm announces the commencement of an investigation of Intellipharmaceutics International Inc.

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Intellipharmaceutics International Inc. (IPCI)

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Intellipharmaceutics International Inc. (IPCI)

The Klein Law Firm announces the commencement of an investigation of Intellipharmaceutics International Inc.

IPCI INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Intellipharmaceutics International Inc.

IPCI INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Intellipharmaceutics International Inc.

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Intellipharmaceutics International Inc.

IPCI SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Intellipharmaceutics International Inc. (IPCI)

IPCI SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Intellipharmaceutics International Inc. (IPCI)

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Intellipharmaceutics International Inc.

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against IntelliPharmaCeutics International Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against IntelliPharmaCeutics International Inc. And Encourages Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against IntelliPharmaCeutics International Inc.

INVESTOR ALERT: Holzer & Holzer Announces Lawsuit Filed On Behalf Of Investors In IntelliPharmaCeutics

INVESTOR ALERT: Holzer & Holzer Announces Lawsuit Filed On Behalf Of Investors In IntelliPharmaCeutics

Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased IntelliPharmaCeutics International, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Intellipharmaceutics International Inc. - IPCI

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Intellipharmaceutics International Inc. - IPCI

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Intellipharmaceutics International Inc.

INTELLIPHARMACEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In IntelliPharmaCeutics International Inc. To Contact The Firm

INTELLIPHARMACEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In IntelliPharmaCeutics International Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at IntelliPharmaCeutics International Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed A Complaint To Recover Losses Suffered By Investors In Intellipharmaceutics International Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed A Complaint To Recover Losses Suffered By Investors In Intellipharmaceutics International Inc.

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Intellipharmaceutics International Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of IntelliPharmaCeutics International Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of IntelliPharmaCeutics International Inc.

Levi & Korsinsky announces it has commenced an investigation of IntelliPharmaCeutics International Inc.

IIROC Trade Resumption - IPCI

IIROC Trade Resumption - IPCI

IIROC Trading Halt - IPCI

IIROC Trading Halt - IPCI

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

IntelliPharmaceuticals has a bio-equivalent to OxyContin, but says it is harder to tamper with. The pharma company is hoping to gain a recommendation from an FDA committee on Wednesday.